Near 35% H1 revenue boost for drugs group Dechra
Pet pharmaceuticals group Dechra has announced half year revenue growth of almost 35%.
The company, which has a large operation in Shrewsbury, said revenue for the six-month period was £172.6m.
Total core revenue grew 6.9% to £131.7m, with core growth in its European division of 5.9% and 10.2% in its North American operation. Excluding a decline in third party contract manufacturing, core European revenue grew by 8.7%
The acquisitions of Genera, Laboratorios Brovel and Putney Inc, together with the acquisition of the business and assets of Apex Laboratories contributed a combined revenue of £40.9m, a growth of £30.9m, the difference of £10m being the prior year Genera contribution and currency movements. Genera and Apex (included in EU Pharmaceuticals) accounted for £5.9m of this, with Brovel and Putney (included in NA Pharmaceuticals) contributing £25m.
“Our core portfolio continues to grow, the enhanced product pipeline is delivering new products and good progress has been made on the rationalisation and integration of our recent acquisitions,” said Dechra CEO Ian Page.
